113. Muscular dystrophy Clinical trials / Disease details
Clinical trials : 622 / Drugs : 485 - (DrugBank : 99) / Drug target genes : 59 - Drug target pathways : 168
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2020-004901-29-PL (EUCTR) | 01/06/2021 | 20/01/2021 | Metoprolol Safety and Efficacy in the Prevention of Cardiomyopathy in Patients with Duchenne Muscular Dystrophy (DMD). | The efficacy and safety of Metoprolol as add-on treatment to standard of care in preventing cardiomyopathy in patients with Duchenne Muscular Dystrophy aged 8-16 years. A randomized, double-blind, placebo controlledstudy. - MeDMD | Duchenne muscular dystrophyCardiomyopathyTachycardia MedDRA version: 20.0;Level: PT;Classification code 10013801;Term: Duchenne muscular dystrophy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Trade Name: Betaloc ZOK 25, 23,75 mg INN or Proposed INN: Metoprolol Other descriptive name: METOPROLOL SUCCINATE Trade Name: Betaloc ZOK 100, 95 mg INN or Proposed INN: Metoprolol Other descriptive name: METOPROLOL SUCCINATE | Medical University of Gdansk | NULL | Authorised-recruitment may be ongoing or finished | Female: no Male: yes | 144 | Phase 3 | Poland |